The short answer: current evidence does not show that semaglutide causes cancer in people
Semaglutide is a medication that mimics a hormone your body makes naturally to control blood sugar and appetite. It is sold under brand names including Ozempic (for diabetes), Wegovy (for weight loss), and Rybelsus. The question of whether it causes cancer has come up because of how the drug works and because of findings in animal studies — but the human evidence available so far does not support that semaglutide itself triggers cancer.
That said, the story is more complicated than a simple yes or no. There are real reasons researchers have looked into this question, and there are things you should understand about what we know and what we are still watching.
Key Takeaways
- Studies in humans taking semaglutide have not found an increase in cancer rates compared to people not taking the drug.
- Animal studies at very high doses showed thyroid tumors, which is why the drug carries a warning label about thyroid cancer risk.
- The warning applies mainly to people with a personal or family history of medullary thyroid cancer or a condition called MEN2 syndrome.
- Weight loss itself may lower cancer risk for some types of cancer, which could offset any theoretical risk from the drug.
- Ongoing monitoring continues because semaglutide is relatively new for weight loss, and long-term human data is still being collected.
Why researchers looked into cancer risk in the first place
The concern started with animal studies. When researchers gave semaglutide to rats and mice at doses much higher than those used in people, some of the animals developed thyroid tumors. This finding triggered a requirement that the drug carry a warning label about potential thyroid cancer risk.
Animal studies do not always predict what will happen in humans — drugs can behave very differently in different species, and the doses used in animals are often far higher than what people receive. Still, the finding was serious enough that it warranted caution and ongoing observation in people actually taking the drug.
Additionally, semaglutide works by stimulating cells in the pancreas and gut. Because cancer can develop in these organs, researchers wanted to make sure the drug was not triggering abnormal cell growth in people.
What human studies have shown so far
The clinical trials that led to semaglutide's approval for weight loss (the Wegovy trials) tracked thousands of people over several years. Researchers looked specifically for cancer cases and compared the rate in people taking semaglutide to the rate in people taking a placebo (a dummy pill with no active ingredient). The result: no meaningful difference in cancer rates between the two groups.
For diabetes patients, semaglutide has been in use longer. Large studies following people with type 2 diabetes who took the drug found no increase in overall cancer risk. Some studies even suggested a slight decrease in certain cancers, though this may be because weight loss and better blood sugar control both lower cancer risk.
These trials were not designed specifically to detect rare cancers or cancers that develop over very long periods. Researchers continue to monitor people taking semaglutide through ongoing safety tracking systems, and new data is added regularly.
The thyroid cancer warning and who it applies to
Because of the animal study findings, semaglutide carries a black box warning — the strongest warning the FDA can place on a medication — about the risk of thyroid cancer. However, this warning is not a blanket prohibition. It applies specifically to people with a personal history of medullary thyroid cancer (a rare type of thyroid cancer) or a family history of this cancer, and to people with a genetic condition called MEN2 syndrome.
If you fall into one of these categories, semaglutide is not recommended for you. Your doctor will ask about your personal and family medical history before prescribing it for this reason. If you are unsure whether you have a family history of medullary thyroid cancer or MEN2, ask relatives or review family medical records before starting the drug.
For people without these specific risk factors, the warning exists as a precaution based on animal data, but human evidence of actual harm has not emerged.
How weight loss itself affects cancer risk
One reason the cancer picture is complicated is that semaglutide causes weight loss, and weight loss itself can lower the risk of several cancers. Obesity is linked to higher rates of breast cancer (in postmenopausal women), colon cancer, endometrial cancer, and others. When people lose weight, their cancer risk for these types may decrease.
This means that even if semaglutide carried a small theoretical risk (which current evidence does not support), that risk might be offset by the protective effect of weight loss. Some researchers have suggested that the net effect of semaglutide on cancer risk could actually be neutral or even slightly protective, though more data is needed to be certain.
What is still being monitored
Semaglutide became widely used for weight loss only in the last few years. While the drug was used for diabetes starting in 2008, the higher doses used for weight loss are newer. This means long-term safety data — tracking people over 10, 20, or 30 years — does not yet exist.
The FDA and drug manufacturers continue to collect safety information from people taking semaglutide. If patterns of cancer or other serious side effects emerge over time, they will be documented and communicated to doctors and patients. This is standard practice for all medications, especially those used by large numbers of people.
Researchers are also conducting additional studies specifically looking at cancer outcomes in people taking semaglutide for weight loss. These studies will add to the evidence base over the next several years.
Questions to ask your doctor before starting semaglutide
If you are considering semaglutide, your doctor should ask about your personal and family medical history, particularly any history of thyroid cancer or MEN2 syndrome. You should also discuss any other health conditions you have, medications you take, and any concerns about cancer risk that are specific to your situation.
Your doctor can weigh the known benefits of the drug (weight loss, better blood sugar control) against any individual risks based on your health history. This conversation is more informative than general statements about whether the drug is "safe," because safety always depends on the individual taking it.
Frequently Asked Questions
If I have a family history of cancer but not thyroid cancer, can I take semaglutide?
Probably yes, but tell your doctor about your family history. The specific warning applies to medullary thyroid cancer and MEN2 syndrome. Other cancer types in your family do not automatically disqualify you, though your doctor may want to discuss your individual risk and whether semaglutide is the right choice for you.
Does semaglutide increase the risk of pancreatic cancer?
Current evidence does not show an increase in pancreatic cancer in people taking semaglutide. However, people with a history of pancreatitis (inflammation of the pancreas) should tell their doctor before starting the drug, as semaglutide can sometimes trigger pancreatitis, which is a separate concern from cancer.
How long do I need to take semaglutide before cancer risk becomes a concern?
Cancer typically develops over years or decades, not weeks or months. There is no specific timeframe after which risk suddenly increases. This is why researchers continue monitoring people taking semaglutide long-term, and why new safety data is reviewed regularly.
If I stop taking semaglutide, does my cancer risk go back to normal?
If semaglutide itself were causing cancer (which current evidence does not support), stopping the drug would likely reduce that risk over time. However, if you stop taking semaglutide and regain weight, any cancer risk reduction from weight loss may also reverse.
Should I get screened for cancer more often if I take semaglutide?
No — current evidence does not support more frequent cancer screening for people taking semaglutide. Follow the standard screening recommendations for your age and health history that your doctor would recommend regardless of whether you take this drug.